Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Saccharomyces cerevisiae

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    24 result(s) found for: Saccharomyces cerevisiae. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2021-000333-13 Sponsor Protocol Number: APHP200046 Start Date*: Information not available in EudraCT
    Sponsor Name:APHP DRCI
    Full Title: Efficacy of the nonavalent HPV vaccine in the treatment of difficult-to-treat palmo-plantar warts
    Medical condition: Vaccination by nonavalent vaccine against HPV could lead to a complete resolution of difficult-to-treat palmo-plantar warts in patients of more than 15 years and 3 months of age
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003591-13 Sponsor Protocol Number: V503-076 Start Date*: 2024-05-06
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 3, Multicenter, Open-Label Study to Evaluate the Safety and Immunogenicity of 2-dose Regimens of 9vHPV and mRNA-1273 SARS-CoV-2 Vaccines Where the First Dose of Each Vaccine Are Given Conco...
    Medical condition: Papilloma viral infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10063001 Human papilloma virus infection LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2024-000582-24 Sponsor Protocol Number: V503-024 Start Date*: 2025-01-10
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 3 Open-Label Clinical Trial to Study the Immunogenicity and Safety of 9-Valent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine (V503) in Chinese females 9 to 45 Years of Age
    Medical condition: Papillomavirus Infections
    Disease: Version SOC Term Classification Code Term Level
    27.1 10021881 - Infections and infestations 10063001 Human papilloma virus infection LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2022-000090-15 Sponsor Protocol Number: 213749 Start Date*: 2022-12-19
    Sponsor Name:GlaxoSmithKline Biologicals SA
    Full Title: A Phase 1/2 randomized, observer-blinded, multi-country study to evaluate safety and immunogenicity of investigational adjuvanted human papillomavirus vaccine in females (16 to 26 years of age)
    Medical condition: Active immunisation for the prevention of human papillomavirus infection
    Disease: Version SOC Term Classification Code Term Level
    21.1 10042613 - Surgical and medical procedures 10071146 Human papilloma virus immunisation PT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: DE (Completed) LT (Completed) FR (Completed) BG (Completed) EE (Completed) CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2009-017374-20 Sponsor Protocol Number: BNI-2009-01 Start Date*: 2010-04-19
    Sponsor Name:Bernhard-Nocht-Institute for Tropical Medicine
    Full Title: Probiotic Saccharomyces boulardii for the prevention of antibiotic-associated diarrhoea – randomised, double-blind, placebo-controlled trial
    Medical condition: Antibiotic - associated - Diarrhoea (AAD) Clostridium difficile - associated - Diarrhoea (CDAD)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10012748 Diarrhoea, Clostridium difficile LLT
    14.1 10021881 - Infections and infestations 10006835 C.difficile diarrhoea LLT
    14.1 10017947 - Gastrointestinal disorders 10055956 Antibiotic-associated diarrhoea LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-004082-20 Sponsor Protocol Number: T502-SIT-059 Start Date*: 2023-03-07
    Sponsor Name:Inmunotek S.L.
    Full Title: An open phase III follow-up study in patients previously treated with mannan-conjugated birch pollen allergoids or placebo in the T502-045 trial.
    Medical condition: Treatment of birch pollen-induced allergic rhinoconjunctivitis.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-002278-24 Sponsor Protocol Number: BPLG-005-RO Start Date*: 2006-10-06
    Sponsor Name:BioPartners GmbH
    Full Title: A phase III, open-label, uncontrolled, multicentre, rollover study to assess safety and efficacy of LB03002 administered weekly in adults with growth hormone deficiency.
    Medical condition: Growth hormone deficiency in adults
    Disease: Version SOC Term Classification Code Term Level
    8.1 10056438 Growth hormone deficiency LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) AT (Completed) GB (Completed) FR (Ongoing) SE (Completed) SK (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-001693-27 Sponsor Protocol Number: 05/Q1606/30 Start Date*: 2005-06-24
    Sponsor Name:Oxford Radcliffe Hospitals NHS Trust
    Full Title: Pilot Effectiveness of Randomised Mandatory Insulin Therapy
    Medical condition: Those admitted to the Intensive Care Unit for treatment and likely to remain on the unit for longer than 5 days.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-004956-35 Sponsor Protocol Number: SGH−ClinPharm−1 Start Date*: 2008-08-27
    Sponsor Name:St George's, University of London
    Full Title: The effect of intensive blood glucose control with insulin on markers of short and medium term outcomes in patients hospitalised with acute exacerbations of chronic lung disease. Pilot Study to te...
    Medical condition: Acute exacerbations of chronic obstructive pulmonary disease. Stress hyperglycaemia. Insulin-induced hypoglycaemia. Cystic fibrosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010953 COPD exacerbation LLT
    9.1 10060439 Stress induced hyperglycaemia LLT
    9.1 10022484 Insulin hypoglycaemia LLT
    9.1 10011762 Cystic fibrosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-005175-18 Sponsor Protocol Number: 151610/06 Start Date*: 2007-09-27
    Sponsor Name:Dpt. of Internal Medicine, Medical University of Innsbruck
    Full Title: Influence of insulin Levemir on endothelial function in type 2 diabetes mellitus. A prospective case-control study.
    Medical condition: Patients with known history of type 2 Diabetes Mellitus longer than 6 months, who were treated by diet in combination with oral antidiabetic drugs (OADs) are to be included in the study.
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-005979-97 Sponsor Protocol Number: 0816202 Start Date*: 2009-01-27
    Sponsor Name:CHU de Toulouse
    Full Title: EFFICACITE DU TRAITEMENT PAR POMPE A INSULINE EXTERNE CHEZ LE DIABETIQUE DE TYPE 2 : ETUDE RANDOMISEE EN PARALLELE SUR 1 AN VERSUS MULTI-INJECTIONS
    Medical condition: diabète de type II
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-003528-39 Sponsor Protocol Number: V503-001 Start Date*: 2007-11-15
    Sponsor Name:Merck & Co. Inc.
    Full Title: A Randomized, International, Double-Blinded (With In-House Blinding), Controlled With GARDASIL™, Dose-Ranging, Tolerability, Immunogenicity, and Efficacy Study of a Multivalent Human Papillomavi...
    Medical condition: Prevention of cervical, vulvar, and vaginal cancers and related precancers, external genital lesions, Pap test abnormalities, and persistent infection caused by Human Papillomavirus (HPV) 6, 11, ...
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004862 10063001 Human papilloma virus infection LLT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: DK (Completed) SE (Completed) DE (Completed) AT (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2008-007020-25 Sponsor Protocol Number: 01 Start Date*: 2009-04-03
    Sponsor Name:AMC
    Full Title: Glucose lowering by continuous tube feeding and Vildagliptin in addition to insulin in hyperglycemic acute stroke patients.
    Medical condition: Hyperglycemia in acute ischemic stroke patients
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020635 Hyperglycaemia LLT
    9.1 10023027 Ischaemic stroke NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-019956-32 Sponsor Protocol Number: - Start Date*: 2010-09-09
    Sponsor Name:Allan Vaag, Steno Diabetes Center
    Full Title: Safety and efficacy of liraglutide as add-on to insulin and metformin therapy in type 2 diabetes patients
    Medical condition: type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    12.1 10012601 Diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-000384-26 Sponsor Protocol Number: BPLG-005 Start Date*: 2005-11-10
    Sponsor Name:LG Life Science Ltd. [...]
    1. LG Life Science Ltd.
    2. BioPartners
    Full Title: A phase III, double-blind, randomized, placebo-controlled, parallel-group, multicenter study to assess efficacy and safety of LB03002 administered weekly in adults with growth hormone deficiency.
    Medical condition: growth hormone deficiency in adults
    Disease: Version SOC Term Classification Code Term Level
    8.0 10056438 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) ES (Ongoing) SE (Completed) CZ (Completed) GB (Completed) SK (Completed) FR (Completed) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-005385-12 Sponsor Protocol Number: GI-5005-02 Start Date*: 2008-04-11
    Sponsor Name:GlobeImmune, Inc.
    Full Title: A Phase 2 Randomized, Open Label, Multi-center, Therapeutic Trial of the Efficacy, Immunogenicity, and Safety of GI-5005; an Inactivated Recombinant Saccharomyces cerevisiae Expressing a Hepatitis ...
    Medical condition: The genotype 1 Chronic Hepatitis C Infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057212 Hepatitis viral infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-005386-35 Sponsor Protocol Number: GI-4000-02 Start Date*: 2008-10-07
    Sponsor Name:GlobeImmune, Inc.
    Full Title: A Phase 2 Double-Blind, Placebo Controlled, Multi-center Adjuvant Trial of the Efficacy, Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant Saccharomyces cerevisiae Expressing Mutant...
    Medical condition: Pancreatic Cancer, post resection R0/R1 status, with tumor sequence confirmation of Ras mutations
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10033575 Pancreas cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-003014-39 Sponsor Protocol Number: MM09-SIT-040 Start Date*: 2022-04-08
    Sponsor Name:Inmunotek, S.L.
    Full Title: Prospective, randomised, double-blind, double-dummy, placebo-controlled multicenter clinical trial of efficacy and safety with immunotherapy in patients with controlled mild to moderate allergic as...
    Medical condition: Etiological treatment of mild to moderate controlled intermittent or persistent allergic asthma and intermittent or persistent allergic rhinitis / rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10020419 House dust mite allergy LLT
    21.1 100000004855 10034382 Perennial allergic rhinitis LLT
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    21.1 100000004855 10001705 Allergic asthma LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-000969-47 Sponsor Protocol Number: 13702908 Start Date*: 2014-07-04
    Sponsor Name:University Hospital of Toulouse
    Full Title: Clinical efficacy of coordinated boluses in type 1 diabetic patients treated with insulin pumps: a multicentric, randomised, cross over study (COBOL study).
    Medical condition: type 1 diabetic patients
    Disease: Version SOC Term Classification Code Term Level
    18.0 10027433 - Metabolism and nutrition disorders 10067584 Type 1 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-001538-41 Sponsor Protocol Number: Start Date*: 2011-06-29
    Sponsor Name:University of Birmingham
    Full Title: The impact of the combination of the GLP-1 analogue liraglutide (Victoza) and laparoscopic adjustable gastric banding (LAGB) on diabetes control
    Medical condition: This trial will investigate the effects of the study treatment arms (gastric band + placebo; gastric band + liraglutide) on diabetes resolution in obese patients.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 28 07:30:01 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA